Regulatory & Legal

USA Pickleball's exclusive DUPR deal aims to unify the sport, but a single rating system brings both professional legitimacy and player controversy.

A seizure of fake Viagra at a Toronto convenience store reveals the dangerous shadow economy of counterfeit drugs threatening public health and business integrity.

Following a strategic merger, the National Down Syndrome Society appoints six new leaders, signaling a new era of inclusive, research-driven advocacy.

Boston-based 1910 Genetics unveils an AI model that bypasses decades-old barriers, opening a vast new frontier for treating Alzheimer's and Parkinson's.

Healthcare tech firm StaffDNA’s title sponsorship of the Cure Bowl is more than a game—it's a calculated move blending branding with a cancer research mission.

A legal fight over attorney fees in the Hess-Chevron deal reveals a costly risk in M&A. Here's why healthcare execs and investors should pay attention.

BlackRock has once again boosted its holding in Finnish drugmaker Orion to over 5%. We decode what this calculated move signals for Orion's future.

New long-term data suggests zorevunersen may modify Dravet syndrome, not just treat it. A look at the science, the strategy, and the stakes.

New data on RAP-219 reveals more than just seizure control; it shows a strategic play to redefine treatment and capture the neurology market.

A routine filing from a quant fund reveals subtle shifts in the high-stakes merger of American Axle and Dowlais. What does it mean for the bottom line?

Intensity Therapeutics has a promising cancer therapy in late-stage trials, but can its scientific innovation outpace a looming Nasdaq delisting threat?

Abaxx is launching UK wind futures, a critical financial tool to manage renewable energy volatility. Is this the key to de-risking the energy transition?

A key regulatory filing reveals growing investor confidence in the American Axle-Dowlais deal, a move poised to reshape the global automotive supply chain.

A shareholder lawsuit challenges Comerica's $10.9B sale to Fifth Third, citing a rushed process, CEO self-interest, and an undervalued price.

Beyond straight teeth, a new aligner offers non-surgical jaw correction for adults, shaking up a multi-billion dollar market. Is this the future?

In a routine filing with major implications, Albion Crown VCT directors reinvest dividends, signaling deep faith in the VCT model as tax rules evolve.

Henri Beaufour’s passing transfers a major Ipsen stake to a charity. We analyze the governance safeguards and what it means when philanthropy enters the boardroom.

A monumental $31.5 billion contract tasks Peraton with replacing the FAA's aging air traffic control system. Can it succeed where others have failed?

As Airbus doubles down in China, the partnership between Paris and Beijing reveals a pragmatic model balancing deep economic ties with a bold geopolitical vision.

The landmark partnership validates China's biotech prowess and injects Takeda's pipeline with next-gen cancer therapies, signaling a major industry shift.